New Drug Evaluation for oral semaglutide (Rybelsus)

14th Oct 2020

The New Drug Evaluation for oral semaglutide (Rybelsus) for the treatment of type 2 diabetes mellitus is now available to stakeholders. This publication provides a concise, structured evaluation of the efficacy, safety, and potential place in therapy for this newly licensed product.